C-Path and PicnicHealth form strategic partnership to advance rare disease research using real-world evidence

Critical Path Institute (C-Path), an independent, nonprofit involved in advancing rare disease research, has unveiled a strategic data collaboration with PicnicHealth, a company dedicated to patient-centric healthcare evidence generation.

This collaboration will integrate C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP^®), renowned for its expertise in data aggregation and analysis, with PicnicHealth’s commitment to patient-driven insights. By combining their strengths, the partnership aims to streamline and enhance the research process, unlock valuable data, and foster collaboration among researchers, clinicians, and patient communities.

The RDCA-DAP platform provides a centralized and standardized approach to accelerate rare disease characterization for clinical development. It promotes best practices in natural history study conduct, upholding established data quality standards, ensuring its value for clinical trial design and regulatory review. The platform’s robust, integrated database and analytics hub facilitate efficient aggregation and interrogation of rare disease data from disparate sources.

Alexandre Bétourné, RDCA-DAP Executive Director commented, “We are excited to receive this EHR dataset from PicnicHealth. Pooling real-world data from multiple sources enables us to amplify RDCA-DAP’s impact in rare disease research and brings us closer to improved treatments and outcomes.”

PicnicHealth’s recent acquisition of AllStripes, a platform dedicated to generating real-world evidence about the rare disease community, underscores its commitment to accelerating advancements in the life sciences. This acquisition further strengthens PicnicHealth’s ability to provide comprehensive patient-driven data to researchers, facilitating the development of more effective treatments for rare diseases.

Nancy Yu, Strategic Advisor at PicnicHealth and former CEO of AllStripes, expressed her conviction in the project’s potential, saying, “The RDCA-DAP mission aligns seamlessly with our mission to empower patients and drive progress in the rare disease space. Together with C-Path’s RDCA-DAP, we are poised to make significant strides in understanding and addressing these often-overlooked conditions.”

---

You may also be interested in:

Where are we now and where are we going? Multi-stakeholder perspectives on the evolution of real-world data